Faruqi & Faruqi, LLP Highlights Upcoming Deadline for Soleno Therapeutics Securities Class Action
In a notable announcement, Faruqi & Faruqi, LLP, a prominent national securities law firm, is advising investors of Soleno Therapeutics, Inc. regarding an imminent deadline for joining a federal securities class action. As the deadline of May 5, 2026 approaches, this notice is particularly relevant for those who purchased securities from Soleno between March 26, 2025, and November 4, 2025. The firm is actively investigating significant claims surrounding the company’s conduct during this time frame, which has drawn investor scrutiny and raised concerns about possible securities law violations.
Faruqi & Faruqi emphasizes the importance for investors who may have sustained losses as a result of potential misrepresentation or failure to disclose critical information by Soleno and its executives. Allegations include that the company’s Phase 3 clinical trial program for its drug DCCR, intended to treat hyperphagia in patients with Prader-Willi syndrome, did not adequately communicate crucial safety risks associated with the medication. This failure had serious implications for investor trust and raised questions about the commercial viability of the drug, particularly in the midst of growing public and regulatory scrutiny.
In August 2025, a report by Scorpion Capital raised alarms regarding the safety and efficacy of DCCR, causing the company's stock price to plunge significantly. Investors witnessed a sharp drop, with the price falling from $77 per share to approximately $68 in just two days. Further compounding these issues, news of a patient death linked to the drug caused another dramatic decline in stock value. By the time of Soleno’s financial results review in November 2025, it became evident that investor confidence had eroded, and the company struggled with fewer patient start forms as well as increased discontinuations. The stock hit a record low during this period, underscoring the extent of the fallout from the adverse events.
Regardless of the outcomes in this case, potential class members are encouraged to consider their rights. The lead plaintiff in such class action suits typically represents those with the largest financial interests involved, although all members may share in any recovery achieved. Faruqi & Faruqi is prepared to assist those who wish to understand their options going forward.
For those wishing to learn more about the specific issues at stake or to assess their options regarding participation in the class action, the firm invites them to reach out directly to recognized securities litigation partner Josh Wilson, who can be contacted at 877-247-4292 or 212-983-9330. This outreach is critical, not only for financial recovery but also for holding corporations accountable for their actions.
As with any legal issues, privacy and confidentiality will be respected during the consultation process. Interested parties are urged to act promptly given the approaching deadline, which will close the opportunity for many involved investors.
Faruqi & Faruqi, LLP has been a cornerstone in securities litigation since 1995, efficiently advocating for investor rights and recovering substantial amounts for clients. Their investigation into Soleno Therapeutics reflects a continuation of this mission as they navigate complex legal waters pertaining to shareholder grievances. Investors are recommended to obtain all the necessary information to make informed decisions concerning their involvement in this crucial lawsuit.
For continuous updates about Soleno Therapeutics and this developing class action, interested parties can follow Faruqi & Faruqi on social media platforms such as LinkedIn, Twitter, and Facebook. Active engagement and communication will ensure that investors remain apprised of the situation as it unfolds. As always, safeguarding your legal rights remains a priority, and Faruqi & Faruqi is dedicated to offering robust legal assistance during this challenging period.
Faruqi & Faruqi emphasizes the importance for investors who may have sustained losses as a result of potential misrepresentation or failure to disclose critical information by Soleno and its executives. Allegations include that the company’s Phase 3 clinical trial program for its drug DCCR, intended to treat hyperphagia in patients with Prader-Willi syndrome, did not adequately communicate crucial safety risks associated with the medication. This failure had serious implications for investor trust and raised questions about the commercial viability of the drug, particularly in the midst of growing public and regulatory scrutiny.
In August 2025, a report by Scorpion Capital raised alarms regarding the safety and efficacy of DCCR, causing the company's stock price to plunge significantly. Investors witnessed a sharp drop, with the price falling from $77 per share to approximately $68 in just two days. Further compounding these issues, news of a patient death linked to the drug caused another dramatic decline in stock value. By the time of Soleno’s financial results review in November 2025, it became evident that investor confidence had eroded, and the company struggled with fewer patient start forms as well as increased discontinuations. The stock hit a record low during this period, underscoring the extent of the fallout from the adverse events.
Regardless of the outcomes in this case, potential class members are encouraged to consider their rights. The lead plaintiff in such class action suits typically represents those with the largest financial interests involved, although all members may share in any recovery achieved. Faruqi & Faruqi is prepared to assist those who wish to understand their options going forward.
For those wishing to learn more about the specific issues at stake or to assess their options regarding participation in the class action, the firm invites them to reach out directly to recognized securities litigation partner Josh Wilson, who can be contacted at 877-247-4292 or 212-983-9330. This outreach is critical, not only for financial recovery but also for holding corporations accountable for their actions.
As with any legal issues, privacy and confidentiality will be respected during the consultation process. Interested parties are urged to act promptly given the approaching deadline, which will close the opportunity for many involved investors.
Faruqi & Faruqi, LLP has been a cornerstone in securities litigation since 1995, efficiently advocating for investor rights and recovering substantial amounts for clients. Their investigation into Soleno Therapeutics reflects a continuation of this mission as they navigate complex legal waters pertaining to shareholder grievances. Investors are recommended to obtain all the necessary information to make informed decisions concerning their involvement in this crucial lawsuit.
For continuous updates about Soleno Therapeutics and this developing class action, interested parties can follow Faruqi & Faruqi on social media platforms such as LinkedIn, Twitter, and Facebook. Active engagement and communication will ensure that investors remain apprised of the situation as it unfolds. As always, safeguarding your legal rights remains a priority, and Faruqi & Faruqi is dedicated to offering robust legal assistance during this challenging period.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.